143 related articles for article (PubMed ID: 22281094)
21. Repeated rituximab maintenance courses in fludarabine-failed young patients with chronic lymphocytic leukaemia responding to FAND chemotherapy.
Scaramucci L; Niscola P; Buffolino S; Bongarzoni V; Cimino G; Montanaro M
Hematol J; 2004; 5(2):186-7. PubMed ID: 15048071
[No Abstract] [Full Text] [Related]
22. Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myeloma.
Fu W; Delasalle K; Wang J; Song S; Hou J; Alexanian R; Wang M
Am J Clin Oncol; 2012 Dec; 35(6):562-5. PubMed ID: 21694573
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of bortezomib, melphalan and low doses dexamethasone (VM-dex) in newly diagnosed patients with multiple myeloma.
Gozzetti A; Defina M; Bocchia M; Fabbri A; Marchini E; Chitarrelli I; Lauria F
Leuk Res; 2010 Nov; 34(11):e288-9. PubMed ID: 20557933
[No Abstract] [Full Text] [Related]
24. Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.
Buda G; Orciuolo E; Galimberti S; Pelosini M; Petrini M
Ann Hematol; 2011 Sep; 90(9):1115-6. PubMed ID: 21181162
[No Abstract] [Full Text] [Related]
25. Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.
Herishanu Y; Goldschmidt N; Bairey O; Ruchlemer R; Fineman R; Rahimi-Levene N; Shvidel L; Tadmor T; Ariel A; Braester A; Shapiro M; Joffe E; Polliack A;
Haematologica; 2015 May; 100(5):662-9. PubMed ID: 25661442
[TBL] [Abstract][Full Text] [Related]
26. [Effect of Velcade combined with Dexamethasone on multiple myeloma].
He Q; Zhao X; He Y; Tan D
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Aug; 35(8):864-7. PubMed ID: 20818081
[TBL] [Abstract][Full Text] [Related]
27. Waldenström macroglobulinemia: my way.
Gertz M
Leuk Lymphoma; 2013 Mar; 54(3):464-71. PubMed ID: 22860921
[TBL] [Abstract][Full Text] [Related]
28. Rituximab in chronic lymphocytic leukemia.
James DF; Kipps TJ
Adv Ther; 2011 Jul; 28(7):534-54. PubMed ID: 21725721
[TBL] [Abstract][Full Text] [Related]
29. Rituximab therapy of severe aplastic anemia induced by fludarabine and cyclophosphamide in a patient affected by B-cell chronic lymphocytic leukemia.
Castiglioni MG; Scatena P; Pandolfo C; Mechelli S; Bianchi M
Leuk Lymphoma; 2006 Sep; 47(9):1985-6. PubMed ID: 17065021
[No Abstract] [Full Text] [Related]
30. Variations on the fludarabine, cyclophosphamide, and rituximab combination in chronic lymphocytic leukemia therapy: what have we learned?
Ahmadi T; Schuster SJ
J Clin Oncol; 2009 Feb; 27(4):479-80. PubMed ID: 19075263
[No Abstract] [Full Text] [Related]
31. Bendamustine: the remedy that came in from the cold.
Lentzsch S
Blood; 2014 Feb; 123(7):948-50. PubMed ID: 24526773
[No Abstract] [Full Text] [Related]
32. [About treatment of multiple myelomas. A report at the 10th International Workshop in Sydney].
Recenti Prog Med; 2005; 96(7-8):405-9. PubMed ID: 16209124
[No Abstract] [Full Text] [Related]
33. CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab.
Yan M; Dong Z; Zhao F; Chauncey T; Deauna-Limayo D; Wang-Rodriguez J; Liu D; Wang HY; Pilz R
Eur J Haematol; 2014 Jul; 93(1):77-80. PubMed ID: 24528507
[TBL] [Abstract][Full Text] [Related]
34. [Efficacy of chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia].
Fang C; Xu W; Xu M; Hong M; Zhu DX; Zhu HY; Wu YJ; Fan L; Qiao C; Zhuang Y; Miao KR; Liu P; Li JY
Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):3-7. PubMed ID: 21429392
[TBL] [Abstract][Full Text] [Related]
35. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
Ruan J; Martin P; Furman RR; Lee SM; Cheung K; Vose JM; Lacasce A; Morrison J; Elstrom R; Ely S; Chadburn A; Cesarman E; Coleman M; Leonard JP
J Clin Oncol; 2011 Feb; 29(6):690-7. PubMed ID: 21189393
[TBL] [Abstract][Full Text] [Related]
36. Paraneoplastic pemphigus despite treatment with rituximab, fludarabine and cyclophosphamide in chronic lymphocytic leukemia.
Schierl M; Foedinger D; Geissler K; Rappersberger K; Feldmann R
Eur J Dermatol; 2008; 18(6):717-8. PubMed ID: 19049939
[No Abstract] [Full Text] [Related]
37. [Bortezomib-based triple combinations (VCD, PAD) for untreated patients with multiple myeloma].
Izumi T
Nihon Rinsho; 2015 Feb; 73 Suppl 2():646-8. PubMed ID: 25831840
[No Abstract] [Full Text] [Related]
38. [Specific palatal infiltration in B-cell chronic lymphocytic leukemia].
Cervigón I; Palomo A; Torres-Iglesias LM; Solano F; Zapata AM
Actas Dermosifiliogr; 2011 May; 102(4):305-7. PubMed ID: 21354544
[No Abstract] [Full Text] [Related]
39. Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma.
Craig M; Hanna WT; Cabanillas F; Chen CS; Esseltine DL; Neuwirth R; O'Connor OA
Br J Haematol; 2014 Sep; 166(6):920-8. PubMed ID: 25039282
[TBL] [Abstract][Full Text] [Related]
40. Light chain deposition.
Hsia CC; Chan NG
Blood; 2013 Jun; 121(26):5111. PubMed ID: 23971090
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
